Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug-Eluting Balloons: New Route to Revascularization

This article was originally published in Start Up

Executive Summary

A few companies with the foresight, even during the heyday of drug-eluting stents, to begin developing drug-eluting balloons are well-positioned to capture one of the next enormous growth markets in cardiology, according to "Current and Emerging US Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies," a report recently published by the Medtech Insight division of FDC-Windhover.

You may also be interested in...



Lutonix: Back To The Future With Drug-Coated Balloons

Drug-coated balloons were once thought to be an unnecessary innovation because of drug-eluting stents. With DES no longer seen as the panacea for vascular disease, balloons could re-emerge as the next major technology platform, and Lutonix is leading the race to bring them to the US market.

Drug-Eluting Balloons: Coming of Age in the Periphery

The jury is still on the ultimate utility of stenting and atherectomy in the distal periphery; meanwhile, all eyes are now on an extremely promising new technology that could be a game-changer for this arena: drug-eluting balloons. DEBs are basically angioplasty balloons coated with an antirestenosis drug that is delivered directly to the vessel wall at the time of balloon inflation. They offer numerous advantages over drug-eluting stents in the superficial femoral artery and distal vessels since they leave no implant behind in the vessel that can fracture or cause hypersensitivity reactions and they eliminate the worries of in-stent restenosis and late-stent thrombosis.They may also provide more uniform distribution of the antiproliferative drug in the vessel wall than stents.

Invatec: Translating Global Success in Vascular Devices to the US Market

Invatec has grown to be the leading native European interventional vascular device company and has now set its sights on the US market. By focusing first on peripherals and following with drug-eluting balloons, not stents, Invatec is looking to compete against the major device companies on their home turf.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel